文献速递痛风与晶体性关节病

2023年美国风湿病学会/欧洲抗风湿病联盟焦磷酸钙沉积病分类标准

The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.
PubMed 文献 · Ann Rheum Dis · 2023-07-26

美国风湿病学会与欧洲抗风湿病联盟首度制定并验证有症状焦磷酸钙沉积病分类标准:入组关节痛、肿胀或压痛且症状无法完全由其他疾病解释者,存在齿突冠综合征或滑液焦磷酸钙晶体即可分类;否则采用加权评分>56分。推导队列敏感度92.2%、特异度87.9%,验证队列敏感度99.2%、特异度92.5%。

要点

  • 入组标准为关节痛、肿胀或压痛,且症状无法完全由其他疾病解释。
  • 齿突冠综合征或滑液焦磷酸钙晶体任一存在即可分类为焦磷酸钙沉积病。
  • 无上述表现时,加权标准评分>56分可分类为焦磷酸钙沉积病。

核心结论

  • 2023年ACR/EULAR焦磷酸钙沉积病分类标准性能优异,将促进该领域研究。

研究设计与样本

  • 由ACR和EULAR支持的多国研究组按既定方法制定分类标准,并在独立队列中验证。

主要发现

  • 推导队列(190例焦磷酸钙沉积病、148例模拟者)敏感度92.2%、特异度87.9%。
  • 验证队列(251例焦磷酸钙沉积病、162例模拟者)敏感度99.2%、特异度92.5%。

关键数值与推荐

  • 入组标准:关节痛、肿胀或压痛,且症状无法完全由其他疾病解释(排除标准)。
  • 齿突冠综合征或滑液焦磷酸钙晶体存在,足以分类为焦磷酸钙沉积病。
  • 无上述发现时,采用包含临床特征、相关代谢疾病及实验室和影像检查结果的加权标准,评分>56分可分类为焦磷酸钙沉积病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease. METHODS: Supported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort. RESULTS: Among patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score>56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers). CONCLUSION: The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Abhishek A, Tedeschi SK, Pascart T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann Rheum Dis. 2023. PMID: 37495237. doi:10.1136/ard-2023-224575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。